REG - OptiBiotix Health - Result of General Meeting <Origin Href="QuoteRef">OPTIO.L</Origin>

OptiBiotix HealthAnnouncement

26/01/2017 14:10

RNS Number : 2341V
OptiBiotix Health PLC
26 January 2017
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Result of General Meetings of Warrant Holders
Further to the announcement made on 23 December 2016, OptiBiotix Health plc (AIM: OPTI), announces that at the General Meeting of Warrant Holders held on 24 January 2017, all resolutions were duly passed.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information:
OptiBiotix Health plc
www.optibiotix.com
Stephen O'Hara, Chief Executive
Contact via Walbrook below


Cairn Financial Advisers LLP
Tel: 020 7213 0880
Liam Murray



finnCap (Broker)
Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)

Tony Quirke (Corporate Broking)



Walbrook PR Ltd
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com 
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
ROMOKADKQBKDNDB